Enzon Expects First-Line Indication For Oncaspar In Mid-2006
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts a supplemental BLA for the pediatric acute lymphoblastic leukemia therapy, the firm announces Dec. 1.